Phathom Pharmaceuticals Inc (PHAT)

$11.03 +0.11 (1.05%)
Market Cap 870.54M
Revenue (ttm) 175.11M
Net Income (ttm) -221.25M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -126.35%
Debt to Equity Ratio -0.49
Volume 1,036,500
Avg Vol 1,169,948
Day's Range N/A - N/A
Shares Out 79.76M
Stochastic %K 28%
Beta 0.49
Analysts Strong Sell
Price Target $23.70

Company Profile

Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases in the United States. It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and related heartburn in adults; and VOQUEZNA Triple Pak and VOQUEZNA Dual Pak that have completed Phase III clinical trials for treating Helicobacter pylori, as well as VOQUEZNA and vonoprazan for t...

Industry: Biotechnology
Sector: Healthcare
Phone: 877 742 8466
Address:
100 Campus Drive, Suite 102, Florham Park, United States
JPhat2026
JPhat2026 Jul. 14 at 1:59 PM
$PHAT ok in for 1500 more hope this is a good discount
2 · Reply
Walleyeslayer
Walleyeslayer Jul. 14 at 1:44 PM
$PHAT Games being played. I figured they would run it down to the low 9's and then do a big short attack before allowing it to run. I still think that may be the gameplan at some point. Monthly buys for me will continue until we are back 18+. GL
1 · Reply
fgggggggg
fgggggggg Jul. 14 at 1:34 PM
$PHAT only the mentally ill are selling. Company could announce profitability any day. Don't be a dope BULLISH AF
0 · Reply
allochthon
allochthon Jul. 14 at 1:11 PM
$PHAT IQVIA normalized Rx 207,212 in Q2, week ending 6/26/26 at 17,112. Total Rx chart up and to the right since bottoming end of January. Q2 consensus revenue $73.8MM, report expected 8/7/26
2 · Reply
fgggggggg
fgggggggg Jul. 13 at 11:51 PM
$PHAT pretty Funny how absolutely retarded and stupid the public markets are. I am more bullish than yesterday and will be more bullish tomorrow. Shorts will have their faves melted off. I am 10000% confident of that.
0 · Reply
Canvasback33
Canvasback33 Jul. 13 at 8:19 PM
$PHAT I’ll take two scoops!! Thank you!!
0 · Reply
Olivia_Strickland
Olivia_Strickland Jul. 13 at 7:44 PM
$PHAT knifing down 11.8% off the 12.61 close, back to 11.12 on the session. these sharp red days can keep bleeding before they base. anyone got a read on what's dragging it here? on my fade list: https://tapeboard.com/go/st/scanner?utm_source=stocktwits&utm_medium=post&utm_campaign=olivia&utm_content=phat-bk-dn-watch&utm_term=scanner&s=PHAT
1 · Reply
fgggggggg
fgggggggg Jul. 13 at 7:39 PM
$PHAT short trap
0 · Reply
Damian23
Damian23 Jul. 13 at 6:48 PM
$PHAT still bullish here but this stock can`t catch a break, wild swings , -12% today on no news, I hope they deliver godd Q2 numbers.
1 · Reply
CH_Expat
CH_Expat Jul. 13 at 6:05 PM
$PHAT Reminds me a bit of IOVA. Not a positive comparison in my world. Undervalued though.
1 · Reply
Latest News on PHAT
Phathom Pharmaceuticals completes enrollment in pHalcon-EoE-201 clinical trial

2026-06-23T12:51:30.000Z - 21 days ago

Phathom Pharmaceuticals completes enrollment in pHalcon-EoE-201 clinical trial

Phathom Pharmaceuticals Completes Patient Enrollment Ahead of Schedule in Phase 2 pHalcon-EoE-201 Study of VOQUEZNA® (vonoprazan) in Eosinophilic Esophagitis (EoE)

Jun 23, 2026, 7:59 AM EDT - 21 days ago

Phathom Pharmaceuticals Completes Patient Enrollment Ahead of Schedule in Phase 2 pHalcon-EoE-201 Study of VOQUEZNA® (vonoprazan) in Eosinophilic Esophagitis (EoE)

Phathom Pharmaceuticals Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 9, 2026, 2:40 PM EDT - 5 weeks ago

Phathom Pharmaceuticals Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Phathom Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2026

Jun 3, 2026, 12:15 PM EDT - 5 weeks ago

Phathom Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2026

Needham pharmaceuticals analysts hold analyst/industry conference call

2026-05-26T19:00:09.000Z - 7 weeks ago

Needham pharmaceuticals analysts hold analyst/industry conference call

Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

May 22, 2026, 8:00 AM EDT - 7 weeks ago

Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

Phathom Pharmaceuticals Highlights Breadth of Independent Vonoprazan Research at Digestive Disease Week 2026 Annual Meeting

May 20, 2026, 8:00 AM EDT - 7 weeks ago

Phathom Pharmaceuticals Highlights Breadth of Independent Vonoprazan Research at Digestive Disease Week 2026 Annual Meeting

Phathom Pharmaceuticals to Highlight VOQUEZNA® (vonoprazan) at DDW 2026 Annual Meeting

May 1, 2026, 8:00 AM EDT - 2 months ago

Phathom Pharmaceuticals to Highlight VOQUEZNA® (vonoprazan) at DDW 2026 Annual Meeting

Phathom Pharmaceuticals reports Q1 non-GAAP EPS (18c), consensus (19c)

2026-04-30T12:05:31.000Z - 2 months ago

Phathom Pharmaceuticals reports Q1 non-GAAP EPS (18c), consensus (19c)

Phathom Pharmaceuticals still sees 2026 revenue $320M-$34M, consensus $332.04M

2026-04-30T12:02:20.000Z - 2 months ago

Phathom Pharmaceuticals still sees 2026 revenue $320M-$34M, consensus $332.04M

Phathom Pharmaceuticals Earnings Call Transcript: Q1 2026

Apr 30, 2026, 8:00 AM EDT - 2 months ago

Phathom Pharmaceuticals Earnings Call Transcript: Q1 2026

Phathom Pharmaceuticals Earnings release: Q1 2026

Apr 30, 2026, 8:00 AM EDT - 2 months ago

Phathom Pharmaceuticals Earnings release: Q1 2026

Phathom Pharmaceuticals Quarterly report: Q1 2026

Apr 30, 2026, 8:00 AM EDT - 2 months ago

Phathom Pharmaceuticals Quarterly report: Q1 2026

Phathom Pharmaceuticals Slides: Q1 2026

Apr 30, 2026, 8:00 AM EDT - 2 months ago

Phathom Pharmaceuticals Slides: Q1 2026

Phathom Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update

Apr 30, 2026, 6:59 AM EDT - 2 months ago

Phathom Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update

Phathom Pharmaceuticals to Report First Quarter 2026 Financial Results and Provide Business Update on Thursday, April 30, 2026

Apr 20, 2026, 8:00 AM EDT - 3 months ago

Phathom Pharmaceuticals to Report First Quarter 2026 Financial Results and Provide Business Update on Thursday, April 30, 2026

Phathom Pharmaceuticals Transcript: 25th Annual Needham Virtual Healthcare Conference

Apr 15, 2026, 1:30 PM EDT - 3 months ago

Phathom Pharmaceuticals Transcript: 25th Annual Needham Virtual Healthcare Conference

Phathom Pharmaceuticals Proxy statement: Proxy filing

Apr 7, 2026, 8:00 AM EDT - 3 months ago

Phathom Pharmaceuticals Proxy statement: Proxy filing

Phathom Pharmaceuticals Proxy statement: Proxy filing

Apr 7, 2026, 8:00 AM EDT - 3 months ago

Phathom Pharmaceuticals Proxy statement: Proxy filing

Phathom Pharmaceuticals upgraded to Overweight from Equal Weight at Barclays

2026-03-27T09:00:23.000Z - 3 months ago

Phathom Pharmaceuticals upgraded to Overweight from Equal Weight at Barclays

Phathom Pharmaceuticals management to meet with Cantor

2026-03-23T18:25:38.000Z - 4 months ago

Phathom Pharmaceuticals management to meet with Cantor

Phathom Pharmaceuticals Transcript: Barclays 28th Annual Global Healthcare Conference

Mar 11, 2026, 3:30 PM EDT - 4 months ago

Phathom Pharmaceuticals Transcript: Barclays 28th Annual Global Healthcare Conference

Phathom Pharmaceuticals Transcript: TD Cowen 46th Annual Health Care Conference

Mar 2, 2026, 10:30 AM EST - 4 months ago

Phathom Pharmaceuticals Transcript: TD Cowen 46th Annual Health Care Conference

Phathom Pharmaceuticals price target raised to $25 from $20 at Guggenheim

2026-02-27T12:39:13.000Z - 4 months ago

Phathom Pharmaceuticals price target raised to $25 from $20 at Guggenheim

Phathom Pharmaceuticals price target raised to $13 from $12 at Goldman Sachs

2026-02-26T23:40:20.000Z - 4 months ago

Phathom Pharmaceuticals price target raised to $13 from $12 at Goldman Sachs

Phathom Pharmaceuticals Earnings Call Transcript: Q4 2025

Feb 26, 2026, 8:00 AM EST - 4 months ago

Phathom Pharmaceuticals Earnings Call Transcript: Q4 2025

Phathom Pharmaceuticals Annual report: Q4 2025

Feb 26, 2026, 8:00 AM EST - 4 months ago

Phathom Pharmaceuticals Annual report: Q4 2025

Phathom Pharmaceuticals Earnings release: Q4 2025

Feb 26, 2026, 8:00 AM EST - 4 months ago

Phathom Pharmaceuticals Earnings release: Q4 2025

Phathom Pharmaceuticals Slides: Q4 2025

Feb 26, 2026, 8:00 AM EST - 4 months ago

Phathom Pharmaceuticals Slides: Q4 2025

Phathom Pharmaceuticals reports Q4 EPS (8c), consensus (19c)

2026-02-26T12:06:11.000Z - 4 months ago

Phathom Pharmaceuticals reports Q4 EPS (8c), consensus (19c)

Phathom Pharmaceuticals sees FY26 net revenues $320M9$345M, consensus $312.56M

2026-02-26T12:05:14.000Z - 4 months ago

Phathom Pharmaceuticals sees FY26 net revenues $320M9$345M, consensus $312.56M

Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Financial Guidance

Feb 26, 2026, 7:00 AM EST - 4 months ago

Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Financial Guidance

Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on Thursday, February 26, 2026

Feb 17, 2026, 8:00 AM EST - 5 months ago

Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on Thursday, February 26, 2026

Phathom Pharmaceuticals Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026

Feb 12, 2026, 11:30 AM EST - 5 months ago

Phathom Pharmaceuticals Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026

Phathom Pharmaceuticals to Present at the Guggenheim Emerging Outlook Biotech Summit 2026

Feb 5, 2026, 8:00 AM EST - 5 months ago

Phathom Pharmaceuticals to Present at the Guggenheim Emerging Outlook Biotech Summit 2026

Phathom Pharmaceuticals 6.875M share Secondary priced at $16.00

2026-01-08T11:31:01.000Z - 6 months ago

Phathom Pharmaceuticals 6.875M share Secondary priced at $16.00

Phathom Pharmaceuticals Announces Pricing of $130 Million Public Offering of Common Stock and Pre-Funded Warrants

Jan 7, 2026, 10:33 PM EST - 6 months ago

Phathom Pharmaceuticals Announces Pricing of $130 Million Public Offering of Common Stock and Pre-Funded Warrants

Phathom Pharmaceuticals announces common stock offering, no amount given

2026-01-07T21:10:45.000Z - 6 months ago

Phathom Pharmaceuticals announces common stock offering, no amount given

Phathom Pharmaceuticals files automatic mixed securities shelf

2026-01-07T21:05:43.000Z - 6 months ago

Phathom Pharmaceuticals files automatic mixed securities shelf

Phathom Pharmaceuticals sees Q4 revenue $57M-$58M, consensus $56.16M

2026-01-07T21:05:23.000Z - 6 months ago

Phathom Pharmaceuticals sees Q4 revenue $57M-$58M, consensus $56.16M

Phathom Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Jan 7, 2026, 4:05 PM EST - 6 months ago

Phathom Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Phathom Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results

Jan 7, 2026, 4:01 PM EST - 6 months ago

Phathom Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results

Phathom Pharmaceuticals Slides: Corporate presentation

Jan 7, 2026, 7:00 AM EST - 6 months ago

Phathom Pharmaceuticals Slides: Corporate presentation

Phathom Pharmaceuticals initiated with a Strong Buy at Raymond James

2025-12-11T21:16:52.000Z - 7 months ago

Phathom Pharmaceuticals initiated with a Strong Buy at Raymond James

Phathom Pharmaceuticals initiated with an Equal Weight at Barclays

2025-12-08T21:30:59.000Z - 7 months ago

Phathom Pharmaceuticals initiated with an Equal Weight at Barclays

Phathom Pharmaceuticals Transcript: Evercore ISI 8th Annual HealthCONx Conference

Dec 2, 2025, 3:25 PM EST - 8 months ago

Phathom Pharmaceuticals Transcript: Evercore ISI 8th Annual HealthCONx Conference

Phathom Pharmaceuticals Transcript: Jefferies London Healthcare Conference 2025

Nov 18, 2025, 9:30 AM EST - 8 months ago

Phathom Pharmaceuticals Transcript: Jefferies London Healthcare Conference 2025

Phathom Pharmaceuticals Transcript: Stifel 2025 Healthcare Conference

Nov 12, 2025, 4:40 PM EST - 8 months ago

Phathom Pharmaceuticals Transcript: Stifel 2025 Healthcare Conference

Phathom Pharmaceuticals Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Nov 10, 2025, 3:00 PM EST - 8 months ago

Phathom Pharmaceuticals Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Phathom Pharmaceuticals Announces First Patient Dosed in Phase 2 Study of VOQUEZNA® (vonoprazan) in Eosinophilic Esophagitis (EoE)

Nov 4, 2025, 8:00 AM EST - 9 months ago

Phathom Pharmaceuticals Announces First Patient Dosed in Phase 2 Study of VOQUEZNA® (vonoprazan) in Eosinophilic Esophagitis (EoE)

Phathom Pharmaceuticals Earnings Call Transcript: Q3 2025

Oct 30, 2025, 8:00 AM EDT - 9 months ago

Phathom Pharmaceuticals Earnings Call Transcript: Q3 2025

Phathom Pharmaceuticals Quarterly report: Q3 2025

Oct 30, 2025, 8:00 AM EDT - 9 months ago

Phathom Pharmaceuticals Quarterly report: Q3 2025

Phathom Pharmaceuticals Earnings release: Q3 2025

Oct 30, 2025, 8:00 AM EDT - 9 months ago

Phathom Pharmaceuticals Earnings release: Q3 2025

Phathom Pharmaceuticals Slides: Q3 2025

Oct 30, 2025, 8:00 AM EDT - 9 months ago

Phathom Pharmaceuticals Slides: Q3 2025

Phathom Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update

Oct 30, 2025, 7:00 AM EDT - 9 months ago

Phathom Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update

Phathom Pharmaceuticals Announces Publication of Data from Phase 3 pHalcon-NERD-301 Study Showing VOQUEZNA® (vonoprazan) Improved Nocturnal GERD Symptoms in Patients with Non-Erosive Reflux Disease

Oct 25, 2025, 9:59 AM EDT - 9 months ago

Phathom Pharmaceuticals Announces Publication of Data from Phase 3 pHalcon-NERD-301 Study Showing VOQUEZNA® (vonoprazan) Improved Nocturnal GERD Symptoms in Patients with Non-Erosive Reflux Disease

Phathom Pharmaceuticals to Highlight VOQUEZNA® (vonoprazan) at the American College of Gastroenterology (ACG) 2025 Annual Scientific Meeting

Oct 23, 2025, 8:00 AM EDT - 9 months ago

Phathom Pharmaceuticals to Highlight VOQUEZNA® (vonoprazan) at the American College of Gastroenterology (ACG) 2025 Annual Scientific Meeting

Phathom Pharmaceuticals to Report Third Quarter 2025 Financial Results and Provide Business Update on Thursday, October 30, 2025

Oct 20, 2025, 8:00 AM EDT - 9 months ago

Phathom Pharmaceuticals to Report Third Quarter 2025 Financial Results and Provide Business Update on Thursday, October 30, 2025

Phathom Pharmaceuticals Appoints Sanjeev Narula as Chief Financial and Business Officer

Oct 6, 2025, 8:00 AM EDT - 10 months ago

Phathom Pharmaceuticals Appoints Sanjeev Narula as Chief Financial and Business Officer

Phathom Pharmaceuticals Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 8, 2025, 1:00 PM EDT - 11 months ago

Phathom Pharmaceuticals Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Phathom Pharmaceuticals Transcript: Cantor Global Healthcare Conference 2025

Sep 3, 2025, 9:10 AM EDT - 11 months ago

Phathom Pharmaceuticals Transcript: Cantor Global Healthcare Conference 2025

Phathom Pharmaceuticals Clarifies That There Is No Reduction in Lead Shareholder's Ownership Following Administrative Change to 13D Filing

Aug 20, 2025, 8:00 AM EDT - 11 months ago

Phathom Pharmaceuticals Clarifies That There Is No Reduction in Lead Shareholder's Ownership Following Administrative Change to 13D Filing

Phathom Pharmaceuticals Earnings Call Transcript: Q2 2025

Aug 7, 2025, 8:00 AM EDT - 1 year ago

Phathom Pharmaceuticals Earnings Call Transcript: Q2 2025

Phathom Pharmaceuticals Quarterly report: Q2 2025

Aug 7, 2025, 8:00 AM EDT - 1 year ago

Phathom Pharmaceuticals Quarterly report: Q2 2025

Phathom Pharmaceuticals Earnings release: Q2 2025

Aug 7, 2025, 8:00 AM EDT - 1 year ago

Phathom Pharmaceuticals Earnings release: Q2 2025

Phathom Pharmaceuticals Slides: Q2 2025

Aug 7, 2025, 8:00 AM EDT - 1 year ago

Phathom Pharmaceuticals Slides: Q2 2025

Phathom Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Updates

Aug 7, 2025, 6:59 AM EDT - 1 year ago

Phathom Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Updates

Phathom Pharmaceuticals to Report Second Quarter 2025 Financial Results and Provide Business Update on Thursday, August 7, 2025

Jul 28, 2025, 8:00 AM EDT - 1 year ago

Phathom Pharmaceuticals to Report Second Quarter 2025 Financial Results and Provide Business Update on Thursday, August 7, 2025

Phathom Pharmaceuticals Slides: Corporate Presentation

Jul 1, 2025, 7:00 AM EDT - 1 year ago

Phathom Pharmaceuticals Slides: Corporate Presentation

Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jun 23, 2025, 4:15 PM EDT - 1 year ago

Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Phathom Pharmaceuticals Appoints Anne Marie Cook as Chief Legal Officer and Corporate Secretary

Jun 23, 2025, 7:59 AM EDT - 1 year ago

Phathom Pharmaceuticals Appoints Anne Marie Cook as Chief Legal Officer and Corporate Secretary

Phathom Pharmaceuticals Announces FDA Correction to Orange Book Listing, Confirming 10 Years of Regulatory Exclusivity for VOQUEZNA® (vonoprazan) Tablets Through May 3, 2032

Jun 16, 2025, 8:00 AM EDT - 1 year ago

Phathom Pharmaceuticals Announces FDA Correction to Orange Book Listing, Confirming 10 Years of Regulatory Exclusivity for VOQUEZNA® (vonoprazan) Tablets Through May 3, 2032

Phathom Pharmaceuticals Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

Jun 11, 2025, 10:40 AM EDT - 1 year ago

Phathom Pharmaceuticals Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

Phathom Pharmaceuticals Announces Positive FDA Decision to Recognize 10 Years of Regulatory Exclusivity for VOQUEZNA® (vonoprazan) Tablets through May 3, 2032

Jun 6, 2025, 12:27 PM EDT - 1 year ago

Phathom Pharmaceuticals Announces Positive FDA Decision to Recognize 10 Years of Regulatory Exclusivity for VOQUEZNA® (vonoprazan) Tablets through May 3, 2032

Phathom Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2025

Jun 5, 2025, 9:55 AM EDT - 1 year ago

Phathom Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2025

Phathom Pharmaceuticals Transcript: AGM 2025

Jun 3, 2025, 11:30 AM EDT - 1 year ago

Phathom Pharmaceuticals Transcript: AGM 2025

Phathom Pharmaceuticals Transcript: H.C. Wainwright 3rd Annual BioConnect Investor Conference 2025

May 20, 2025, 4:00 PM EDT - 1 year ago

Phathom Pharmaceuticals Transcript: H.C. Wainwright 3rd Annual BioConnect Investor Conference 2025

Phathom Pharmaceuticals Earnings Call Transcript: Q1 2025

May 1, 2025, 8:00 AM EDT - 1 year ago

Phathom Pharmaceuticals Earnings Call Transcript: Q1 2025

Phathom Pharmaceuticals Earnings release: Q1 2025

May 1, 2025, 8:00 AM EDT - 1 year ago

Phathom Pharmaceuticals Earnings release: Q1 2025

Phathom Pharmaceuticals Quarterly report: Q1 2025

May 1, 2025, 8:00 AM EDT - 1 year ago

Phathom Pharmaceuticals Quarterly report: Q1 2025

Phathom Pharmaceuticals Slides: Q1 2025

May 1, 2025, 8:00 AM EDT - 1 year ago

Phathom Pharmaceuticals Slides: Q1 2025

Phathom Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

May 1, 2025, 7:00 AM EDT - 1 year ago

Phathom Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

ITCI

Phathom Pharmaceuticals Slides: Corporate Presentation

May 1, 2025, 7:00 AM EDT - 1 year ago

Phathom Pharmaceuticals Slides: Corporate Presentation

Phathom Pharmaceuticals to Present VOQUEZNA® (vonoprazan) Data at DDW 2025 Annual Meeting

Apr 28, 2025, 7:59 AM EDT - 1 year ago

Phathom Pharmaceuticals to Present VOQUEZNA® (vonoprazan) Data at DDW 2025 Annual Meeting

Phathom Pharmaceuticals to Report First Quarter 2025 Financial Results and Provide Business Update on Thursday, May 1, 2025

Apr 23, 2025, 8:00 AM EDT - 1 year ago

Phathom Pharmaceuticals to Report First Quarter 2025 Financial Results and Provide Business Update on Thursday, May 1, 2025

Phathom Pharmaceuticals Proxy statement: Proxy Filing

Apr 23, 2025, 8:00 AM EDT - 1 year ago

Phathom Pharmaceuticals Proxy statement: Proxy Filing

Phathom Pharmaceuticals Proxy statement: Proxy Filing

Apr 23, 2025, 8:00 AM EDT - 1 year ago

Phathom Pharmaceuticals Proxy statement: Proxy Filing

Frazier Life Sciences Appoints Aditya Kohli to Partner

Apr 17, 2025, 8:00 AM EDT - 1 year ago

Frazier Life Sciences Appoints Aditya Kohli to Partner

Phathom Pharmaceuticals Appoints Ted Schroeder to its Board of Directors

Apr 16, 2025, 8:00 AM EDT - 1 year ago

Phathom Pharmaceuticals Appoints Ted Schroeder to its Board of Directors

CDTX

Phathom Pharmaceuticals Transcript: 24th Annual Needham Virtual Healthcare Conference

Apr 8, 2025, 10:15 AM EDT - 1 year ago

Phathom Pharmaceuticals Transcript: 24th Annual Needham Virtual Healthcare Conference

Phathom Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference

Apr 3, 2025, 8:00 AM EDT - 1 year ago

Phathom Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference

Phathom Pharmaceuticals Announces Leadership Succession

Apr 1, 2025, 8:00 AM EDT - 1 year ago

Phathom Pharmaceuticals Announces Leadership Succession

Actor and Comedian Kenan Thompson Teams Up with Phathom Pharmaceuticals to Raise Awareness About GERD and VOQUEZNA® (vonoprazan)

Mar 31, 2025, 7:59 AM EDT - 1 year ago

Actor and Comedian Kenan Thompson Teams Up with Phathom Pharmaceuticals to Raise Awareness About GERD and VOQUEZNA® (vonoprazan)

Phathom Pharmaceuticals Earnings Call Transcript: Q4 2024

Mar 6, 2025, 8:30 AM EST - 1 year ago

Phathom Pharmaceuticals Earnings Call Transcript: Q4 2024

Phathom Pharmaceuticals Annual report: Q4 2024

Mar 6, 2025, 8:30 AM EST - 1 year ago

Phathom Pharmaceuticals Annual report: Q4 2024

Phathom Pharmaceuticals Earnings release: Q4 2024

Mar 6, 2025, 8:30 AM EST - 1 year ago

Phathom Pharmaceuticals Earnings release: Q4 2024

Phathom Pharmaceuticals Slides: Q4 2024

Mar 6, 2025, 8:30 AM EST - 1 year ago

Phathom Pharmaceuticals Slides: Q4 2024

Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Mar 6, 2025, 8:00 AM EST - 1 year ago

Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on Thursday, March 6, 2025

Feb 24, 2025, 8:00 AM EST - 1 year ago

Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on Thursday, March 6, 2025

Phathom Pharmaceuticals Transcript: Guggenheim SMID Cap Biotech Conference

Feb 6, 2025, 10:00 AM EST - 1 year ago

Phathom Pharmaceuticals Transcript: Guggenheim SMID Cap Biotech Conference

Phathom Pharmaceuticals to Present at the Guggenheim Securities SMID Cap Biotech Conference

Jan 29, 2025, 8:00 AM EST - 1 year ago

Phathom Pharmaceuticals to Present at the Guggenheim Securities SMID Cap Biotech Conference

Phathom Pharmaceuticals Slides: Corporate Presentation

Dec 11, 2024, 12:00 PM EST - 1 year ago

Phathom Pharmaceuticals Slides: Corporate Presentation

Phathom Pharmaceuticals Submits Citizen Petition to FDA Seeking Correction of Orange Book Listings for VOQUEZNA® (vonoprazan) Tablets

Dec 11, 2024, 8:00 AM EST - 1 year ago

Phathom Pharmaceuticals Submits Citizen Petition to FDA Seeking Correction of Orange Book Listings for VOQUEZNA® (vonoprazan) Tablets

Phathom Pharmaceuticals Transcript: 7th Annual Evercore ISI HealthCONx Conference

Dec 3, 2024, 2:10 PM EST - 1 year ago

Phathom Pharmaceuticals Transcript: 7th Annual Evercore ISI HealthCONx Conference

Phathom Pharmaceuticals Transcript: Stifel 2024 Healthcare Conference

Nov 18, 2024, 1:15 PM EST - 1 year ago

Phathom Pharmaceuticals Transcript: Stifel 2024 Healthcare Conference

Phathom Pharmaceuticals Transcript: Guggenheim’s Inaugural Healthcare Innovation Conference

Nov 12, 2024, 9:30 AM EST - 1 year ago

Phathom Pharmaceuticals Transcript: Guggenheim’s Inaugural Healthcare Innovation Conference

Phathom Pharmaceuticals Earnings Call Transcript: Q3 2024

Nov 7, 2024, 8:30 AM EST - 1 year ago

Phathom Pharmaceuticals Earnings Call Transcript: Q3 2024

Phathom Pharmaceuticals Quarterly report: Q3 2024

Nov 7, 2024, 8:30 AM EST - 1 year ago

Phathom Pharmaceuticals Quarterly report: Q3 2024

Phathom Pharmaceuticals Earnings release: Q3 2024

Nov 7, 2024, 8:30 AM EST - 1 year ago

Phathom Pharmaceuticals Earnings release: Q3 2024

Phathom Pharmaceuticals Slides: Q3 2024

Nov 7, 2024, 8:30 AM EST - 1 year ago

Phathom Pharmaceuticals Slides: Q3 2024

Phathom Pharmaceuticals to Report Third Quarter 2024 Financial Results and Provide Business Update on Thursday, November 7, 2024

Oct 28, 2024, 8:00 AM EDT - 1 year ago

Phathom Pharmaceuticals to Report Third Quarter 2024 Financial Results and Provide Business Update on Thursday, November 7, 2024

Phathom Pharmaceuticals to Present VOQUEZNA® Data at the American College of Gastroenterology (ACG) 2024 Annual Meeting

Oct 27, 2024, 12:00 PM EDT - 1 year ago

Phathom Pharmaceuticals to Present VOQUEZNA® Data at the American College of Gastroenterology (ACG) 2024 Annual Meeting

Phathom Pharmaceuticals Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

Sep 9, 2024, 12:00 PM EDT - 2 years ago

Phathom Pharmaceuticals Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

Phathom Pharmaceuticals Announces Pricing of $130 Million Offering of Common Stock and Pre-Funded Warrants

Aug 19, 2024, 8:00 AM EDT - 2 years ago

Phathom Pharmaceuticals Announces Pricing of $130 Million Offering of Common Stock and Pre-Funded Warrants

Phathom Pharmaceuticals Earnings Call Transcript: Q2 2024

Aug 8, 2024, 8:30 AM EDT - 2 years ago

Phathom Pharmaceuticals Earnings Call Transcript: Q2 2024

Phathom Pharmaceuticals Quarterly report: Q2 2024

Aug 8, 2024, 8:30 AM EDT - 2 years ago

Phathom Pharmaceuticals Quarterly report: Q2 2024

Phathom Pharmaceuticals Earnings release: Q2 2024

Aug 8, 2024, 8:30 AM EDT - 2 years ago

Phathom Pharmaceuticals Earnings release: Q2 2024

Phathom Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update

Aug 8, 2024, 8:00 AM EDT - 2 years ago

Phathom Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update

Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA® (vonoprazan) Tablets for the Relief of Heartburn Associated with Non-Erosive GERD in Adults

Jul 18, 2024, 8:00 AM EDT - 2 years ago

Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA® (vonoprazan) Tablets for the Relief of Heartburn Associated with Non-Erosive GERD in Adults

Phathom Pharmaceuticals Transcript: Goldman Sachs 45th Annual Global Healthcare Conference

Jun 11, 2024, 2:40 PM EDT - 2 years ago

Phathom Pharmaceuticals Transcript: Goldman Sachs 45th Annual Global Healthcare Conference

Phathom Pharmaceuticals Transcript: Jefferies Global Healthcare Conference

Jun 5, 2024, 12:30 PM EDT - 2 years ago

Phathom Pharmaceuticals Transcript: Jefferies Global Healthcare Conference

Phathom Pharmaceuticals Transcript: AGM 2024

May 23, 2024, 10:00 AM EDT - 2 years ago

Phathom Pharmaceuticals Transcript: AGM 2024

Phathom Pharmaceuticals Earnings Call Transcript: Q1 2024

May 9, 2024, 8:30 AM EDT - 2 years ago

Phathom Pharmaceuticals Earnings Call Transcript: Q1 2024

Phathom Pharmaceuticals Quarterly report: Q1 2024

May 9, 2024, 8:30 AM EDT - 2 years ago

Phathom Pharmaceuticals Quarterly report: Q1 2024

Phathom Pharmaceuticals Earnings release: Q1 2024

May 9, 2024, 8:30 AM EDT - 2 years ago

Phathom Pharmaceuticals Earnings release: Q1 2024

Phathom Pharmaceuticals Slides: Q1 2024

May 9, 2024, 8:30 AM EDT - 2 years ago

Phathom Pharmaceuticals Slides: Q1 2024

Phathom Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update

May 9, 2024, 8:00 AM EDT - 2 years ago

Phathom Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update

Phathom Pharmaceuticals Proxy statement: Proxy Filing

Apr 12, 2024, 8:00 AM EDT - 2 years ago

Phathom Pharmaceuticals Proxy statement: Proxy Filing

Phathom Pharmaceuticals Proxy statement: Proxy Filing

Apr 12, 2024, 8:00 AM EDT - 2 years ago

Phathom Pharmaceuticals Proxy statement: Proxy Filing

Phathom Pharmaceuticals Transcript: 23rd Annual Needham Virtual Healthcare Conference

Apr 10, 2024, 9:30 AM EDT - 2 years ago

Phathom Pharmaceuticals Transcript: 23rd Annual Needham Virtual Healthcare Conference

Phathom Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference

Apr 3, 2024, 8:00 AM EDT - 2 years ago

Phathom Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference

Phathom Pharmaceuticals Launches Direct-to-Consumer Campaign, “VOQUEZNA Can Kick Some Acid”

Mar 26, 2024, 8:00 AM EDT - 2 years ago

Phathom Pharmaceuticals Launches Direct-to-Consumer Campaign, “VOQUEZNA Can Kick Some Acid”

Phathom Pharmaceuticals Earnings Call Transcript: Q4 2023

Mar 7, 2024, 8:30 AM EST - 2 years ago

Phathom Pharmaceuticals Earnings Call Transcript: Q4 2023

Phathom Pharmaceuticals Annual report: Q4 2023

Mar 7, 2024, 8:30 AM EST - 2 years ago

Phathom Pharmaceuticals Annual report: Q4 2023

Phathom Pharmaceuticals Earnings release: Q4 2023

Mar 7, 2024, 8:30 AM EST - 2 years ago

Phathom Pharmaceuticals Earnings release: Q4 2023

Phathom Pharmaceuticals Slides: Q4 2023

Mar 7, 2024, 8:30 AM EST - 2 years ago

Phathom Pharmaceuticals Slides: Q4 2023

Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Mar 7, 2024, 8:00 AM EST - 2 years ago

Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Thursday, March 7, 2024

Feb 29, 2024, 8:00 AM EST - 2 years ago

Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Thursday, March 7, 2024

Phathom Pharmaceuticals Transcript: Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference

Feb 7, 2024, 1:30 PM EST - 2 years ago

Phathom Pharmaceuticals Transcript: Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference

Phathom Pharmaceuticals to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Jan 31, 2024, 8:00 AM EST - 2 years ago

Phathom Pharmaceuticals to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Phathom Pharmaceuticals Slides: Investor Presentation

Dec 18, 2023, 11:00 AM EST - 2 years ago

Phathom Pharmaceuticals Slides: Investor Presentation

Phathom Pharmaceuticals Announces FDA Acceptance for Filing of VOQUEZNA® (vonoprazan) Tablets New Drug Application for the Treatment of Heartburn Associated with Non-Erosive GERD

Dec 6, 2023, 8:00 AM EST - 2 years ago

Phathom Pharmaceuticals Announces FDA Acceptance for Filing of VOQUEZNA® (vonoprazan) Tablets New Drug Application for the Treatment of Heartburn Associated with Non-Erosive GERD

JPhat2026
JPhat2026 Jul. 14 at 1:59 PM
$PHAT ok in for 1500 more hope this is a good discount
2 · Reply
Walleyeslayer
Walleyeslayer Jul. 14 at 1:44 PM
$PHAT Games being played. I figured they would run it down to the low 9's and then do a big short attack before allowing it to run. I still think that may be the gameplan at some point. Monthly buys for me will continue until we are back 18+. GL
1 · Reply
fgggggggg
fgggggggg Jul. 14 at 1:34 PM
$PHAT only the mentally ill are selling. Company could announce profitability any day. Don't be a dope BULLISH AF
0 · Reply
allochthon
allochthon Jul. 14 at 1:11 PM
$PHAT IQVIA normalized Rx 207,212 in Q2, week ending 6/26/26 at 17,112. Total Rx chart up and to the right since bottoming end of January. Q2 consensus revenue $73.8MM, report expected 8/7/26
2 · Reply
fgggggggg
fgggggggg Jul. 13 at 11:51 PM
$PHAT pretty Funny how absolutely retarded and stupid the public markets are. I am more bullish than yesterday and will be more bullish tomorrow. Shorts will have their faves melted off. I am 10000% confident of that.
0 · Reply
Canvasback33
Canvasback33 Jul. 13 at 8:19 PM
$PHAT I’ll take two scoops!! Thank you!!
0 · Reply
Olivia_Strickland
Olivia_Strickland Jul. 13 at 7:44 PM
$PHAT knifing down 11.8% off the 12.61 close, back to 11.12 on the session. these sharp red days can keep bleeding before they base. anyone got a read on what's dragging it here? on my fade list: https://tapeboard.com/go/st/scanner?utm_source=stocktwits&utm_medium=post&utm_campaign=olivia&utm_content=phat-bk-dn-watch&utm_term=scanner&s=PHAT
1 · Reply
fgggggggg
fgggggggg Jul. 13 at 7:39 PM
$PHAT short trap
0 · Reply
Damian23
Damian23 Jul. 13 at 6:48 PM
$PHAT still bullish here but this stock can`t catch a break, wild swings , -12% today on no news, I hope they deliver godd Q2 numbers.
1 · Reply
CH_Expat
CH_Expat Jul. 13 at 6:05 PM
$PHAT Reminds me a bit of IOVA. Not a positive comparison in my world. Undervalued though.
1 · Reply
TeeMan123
TeeMan123 Jul. 13 at 5:39 PM
$PHAT green close LFG
1 · Reply
fgggggggg
fgggggggg Jul. 13 at 5:29 PM
$PHAT fake trading that follows the same playbook. I know what I own BULLISH AF
1 · Reply
Olivia_Strickland
Olivia_Strickland Jul. 13 at 3:38 PM
$PHAT giving it back, down near 10% off that 12.61 close and hanging at 11.36. these fast pullbacks can overshoot before they find a floor. i'm letting it settle before I trust any bounce. what level you guys got as support here? on my fade list: https://tapeboard.com/go/st/scanner?utm_source=stocktwits&utm_medium=post&utm_campaign=olivia&utm_content=phat-bk-dn-watch&utm_term=scanner&s=PHAT
0 · Reply
Joe_90_
Joe_90_ Jul. 13 at 3:34 PM
$PHAT wondering are we on the verge of a BO?, in my very limited experience ive always seen price depressed before the rapid increase
1 · Reply
StardustTrader
StardustTrader Jul. 13 at 3:32 PM
$PHAT pure algo. Just look at the technicals. Nothing to be concerned with right now.
0 · Reply
TexasMade
TexasMade Jul. 13 at 3:20 PM
$PHAT is Fat. Different spelling... same meaning... a package wraped different is still a package.
0 · Reply
Joe_90_
Joe_90_ Jul. 13 at 3:05 PM
$PHAT opportunity
0 · Reply
lowfloatscambuster
lowfloatscambuster Jul. 13 at 2:58 PM
$PHAT Seems like we have a lot of bio noobs here
0 · Reply
Withermania
Withermania Jul. 13 at 2:56 PM
$PHAT sympathy sell on XBI. Once again the baby is thrown out with the bath water creating epic opportunities. Buying with both hands once again.
0 · Reply
Morrito23
Morrito23 Jul. 13 at 2:38 PM
$PHAT I think we should start seeing some support again soon. Fingers crossed. This is what I was saying with my overbought comment. In my opinion, this is still healthy.
0 · Reply
Randy_Lahey_Trevor_Corey
Randy_Lahey_Trevor_Corey Jul. 13 at 2:37 PM
$PHAT what in the actual fuck
0 · Reply
fgggggggg
fgggggggg Jul. 13 at 1:36 PM
$PHAT Only the mentally ill would sell here
1 · Reply